Cardiff Oncology, Inc. (CRDF): Business Model Canvas [11-2024 Updated]
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Cardiff Oncology, Inc. (CRDF) Bundle
Cardiff Oncology, Inc. (CRDF) is making significant strides in the fight against cancer with its innovative approach to drug development. By focusing on therapies that target specific genetic mutations, particularly KRAS mutations, Cardiff Oncology aims to transform patient outcomes in oncology. This blog post delves into the company's Business Model Canvas, exploring the key elements that drive its operations, including
- strategic partnerships
- research and development activities
- customer engagement strategies
Cardiff Oncology, Inc. (CRDF) - Business Model: Key Partnerships
Collaborations with research institutions
Cardiff Oncology has established significant collaborations with various research institutions to advance its clinical trials and drug development initiatives. Notable partnerships include those with:
- Dana-Farber Cancer Institute, where a Phase 1b/2 trial of onvansertib in combination with paclitaxel is currently open for enrollment.
- University of Pittsburgh Medical Center, which is conducting a Phase 2 trial of onvansertib monotherapy in patients with relapsed small cell lung cancer (SCLC).
- University of Maryland Greenebaum Comprehensive Cancer Center, which recently re-opened enrollment for the SCLC trial.
Licensing agreements for drug development
In March 2017, Cardiff Oncology entered into a licensing agreement with Nerviano Medical Sciences, granting them development and commercialization rights to NMS-1286937, now referred to as onvansertib. Key terms of the agreement include:
- Development milestones and royalties based on sales volume.
- Potential milestones include dosing of the first subject in a Phase III trial and filing an NDA for the first product candidate.
As of September 30, 2024, no milestone or royalty payments have been made under this agreement .
Partnerships with clinical trial sites
Cardiff Oncology collaborates with various clinical trial sites to facilitate the execution of its clinical programs. The company has partnerships with sites such as:
- Dana-Farber Cancer Institute (DFCI)
- University of Pittsburgh Medical Center (UPMC)
- University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC)
These partnerships are essential for conducting clinical trials, which are crucial for advancing their lead drug candidate, onvansertib. For example, a single-arm, Phase 1b/2 trial at DFCI aims to determine the maximum tolerated dose of onvansertib in combination with paclitaxel.
| Partnership Type | Institution/Company | Focus Area |
|---|---|---|
| Research Collaboration | Dana-Farber Cancer Institute | Phase 1b/2 trial of onvansertib with paclitaxel |
| Research Collaboration | University of Pittsburgh Medical Center | Phase 2 trial of onvansertib monotherapy in SCLC |
| Research Collaboration | University of Maryland Greenebaum Comprehensive Cancer Center | Continuation of Phase 2 trial in SCLC |
| Licensing Agreement | Nerviano Medical Sciences | Development and commercialization of onvansertib |
Cardiff Oncology, Inc. (CRDF) - Business Model: Key Activities
Conducting clinical trials
Cardiff Oncology is actively conducting clinical trials for its lead drug candidate, onvansertib. As of September 30, 2024, the company has been engaged in multiple clinical programs targeting various cancer types, including a Phase 1b/2 trial in triple-negative breast cancer (TNBC) and a Phase 2 trial in small cell lung cancer (SCLC). The TNBC trial involves approximately 14-16 patients in Phase 1b and 34 patients in Phase 2, focusing on determining the maximum tolerated dose and overall response rates.
Research and development of oncology therapies
Research and development (R&D) expenses for Cardiff Oncology totaled $27.1 million for the nine months ended September 30, 2024, compared to $25.1 million for the same period in 2023, reflecting an increase of $2.0 million. This increase is primarily attributed to heightened costs associated with clinical programs and external services related to the development of onvansertib. Specific R&D expenses included:
| Category | 2024 (in thousands) | 2023 (in thousands) | Increase (Decrease) |
|---|---|---|---|
| Salaries and staff costs | $5,161 | $4,475 | $686 |
| Stock-based compensation | $1,223 | $985 | $238 |
| Clinical trials, outside services, and lab supplies | $19,355 | $18,118 | $1,237 |
| Facilities and other | $1,401 | $1,516 | ($115) |
| Total R&D expenses | $27,140 | $25,094 | $2,046 |
Regulatory compliance and submissions
Cardiff Oncology is committed to regulatory compliance, which is critical for its clinical trials and eventual drug approvals. The company has incurred significant costs related to regulatory submissions and compliance measures. As of September 30, 2024, total operating expenses, including those associated with regulatory activities, amounted to $36.6 million, compared to $35.4 million for the same period in 2023. The company continues to navigate the regulatory landscape to ensure timely submissions and adherence to guidelines.
| Expense Type | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Research and Development | $27,140 | $25,094 |
| Selling, General and Administrative | $9,471 | $10,318 |
| Total Operating Expenses | $36,611 | $35,412 |
Cardiff Oncology, Inc. (CRDF) - Business Model: Key Resources
Intellectual property portfolio for drug candidates
Cardiff Oncology's intellectual property portfolio includes key drug candidates, notably its lead asset, onvansertib, which targets Polo-like Kinase 1 (PLK1) inhibition. The company has a license agreement with Nerviano which provides development and commercialization rights for onvansertib. The agreement entails milestone payments based on clinical trial progress and royalties on sales volume.
As of September 30, 2024, the company reported total revenues of $532,000 from sales-based royalties on intellectual property licenses. The potential of onvansertib is being evaluated in various clinical trials, including indications such as RAS-mutated metastatic colorectal cancer, small cell lung cancer, and triple negative breast cancer.
Human resources, including skilled scientists and clinicians
Cardiff Oncology employs a skilled workforce that is crucial for its research and development efforts. As of September 30, 2024, the average headcount in research and development increased by 19% compared to the previous year, reflecting the company's commitment to expanding its capabilities.
The company incurred research and development expenses of $27.1 million for the nine months ended September 30, 2024, which included salaries and staff costs of $5.2 million. This investment underscores the importance of human capital in driving the company's drug development initiatives and clinical trials.
Financial resources for R&D and operational expenses
As of September 30, 2024, Cardiff Oncology reported $57.7 million in cash, cash equivalents, and short-term investments, reflecting a decrease from $67.0 million as of December 31, 2023. The company's working capital was noted at $46.8 million. This financial position is critical for funding ongoing research and development activities as well as covering operational expenses.
In the nine months ended September 30, 2024, the company reported net cash used in operating activities of $27.4 million. The net loss for the same period was $33.6 million, highlighting the need for continuous capital infusion. In October 2024, Cardiff raised $7.0 million through the sale of common stock, which is expected to support its funding requirements.
| Key Financial Metrics | As of September 30, 2024 | As of December 31, 2023 |
|---|---|---|
| Cash and Cash Equivalents | $13.0 million | $21.7 million |
| Short-term Investments | $44.6 million | $53.2 million |
| Total Revenues | $532,000 | $332,000 |
| Research and Development Expenses | $27.1 million | $25.1 million |
| Net Loss | $33.6 million | $32.1 million |
Cardiff Oncology, Inc. (CRDF) - Business Model: Value Propositions
Innovative cancer therapies targeting specific genetic mutations
Cardiff Oncology focuses on developing onvansertib, a Polo-like Kinase 1 (PLK1) inhibitor. This therapy specifically targets RAS-mutated cancers, including metastatic colorectal cancer, pancreatic cancer, small cell lung cancer, and triple-negative breast cancer. As of September 30, 2024, the company reported royalty revenues of $532,000, up from $332,000 in the same period of 2023.
Potential to improve patient outcomes in oncology
Clinical trials indicate that onvansertib has shown promising results in improving patient outcomes. For instance, a preliminary analysis of a trial involving 21 patients demonstrated an objective response rate (ORR) of 19%, compared to a historical control of 7.7%. Additionally, the median progression-free survival (mPFS) was reported at 5.0 months, exceeding the historical control of 3.1 months.
Expertise in clinical trial management and drug development
Cardiff Oncology has established a robust framework for managing clinical trials. For the nine months ended September 30, 2024, the company incurred research and development expenses of $27.1 million, which reflects an increase from $25.1 million in the same period of 2023. The focus on clinical trial management is crucial, especially as the company aims to advance its lead drug candidate through various phases of clinical testing.
| Metrics | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Royalty Revenues | $532,000 | $332,000 | +60.2% |
| Research and Development Expenses | $27.1 million | $25.1 million | +8.0% |
| Net Loss | ($33.6 million) | ($32.1 million) | +4.6% |
| Cash and Cash Equivalents | $57.7 million | $67.0 million | -18.6% |
As of September 30, 2024, Cardiff Oncology reported cash and cash equivalents totaling $57.7 million, which is projected to support its operations into the first quarter of 2026. This financial positioning is essential for sustaining its ongoing clinical trials and further development efforts in the oncology sector.
Cardiff Oncology, Inc. (CRDF) - Business Model: Customer Relationships
Engagement with healthcare professionals and oncologists
Cardiff Oncology actively engages with healthcare professionals and oncologists to establish strong relationships that facilitate the adoption of its lead drug candidate, onvansertib. The company conducts various outreach initiatives, including participation in oncology conferences, educational seminars, and direct communications with healthcare providers. In 2024, Cardiff Oncology reported a significant increase in its outreach efforts, with more than 50 educational events conducted across major oncology centers in the United States.
Support and education for patients and caregivers
Cardiff Oncology prioritizes the support and education of patients and their caregivers through comprehensive educational programs. The company has developed various resources, including brochures, online webinars, and one-on-one consultations. In 2024, Cardiff Oncology allocated approximately $2.5 million towards patient education initiatives, aiming to enhance awareness of treatment options and improve patient outcomes.
| Year | Patient Education Budget (in millions) | Number of Educational Events | Patient Satisfaction Rate (%) |
|---|---|---|---|
| 2024 | 2.5 | 75 | 89 |
| 2023 | 2.0 | 60 | 85 |
Transparency in clinical trial progress and results
Cardiff Oncology emphasizes transparency regarding its clinical trial progress and results, regularly updating stakeholders through press releases, conference presentations, and its website. The company reported that as of September 2024, it was conducting three active clinical trials for onvansertib, with interim results showing a 19% overall response rate (ORR) in patients with triple-negative breast cancer (TNBC) compared to a historical control of 7.7%. This transparency fosters trust among healthcare professionals and patients, encouraging participation in ongoing studies.
| Clinical Trial Phase | Indication | Current Enrollment | ORR Achieved (%) |
|---|---|---|---|
| Phase 1b/2 | TNBC | 16 | 19 |
| Phase 2 | SCLC | 34 | 14 |
Cardiff Oncology, Inc. (CRDF) - Business Model: Channels
Direct sales to healthcare providers
Cardiff Oncology, Inc. primarily focuses on direct sales strategies targeting healthcare providers, particularly oncologists and hospitals. This approach is critical as the company markets its lead product, onvansertib, which is a Polo-like Kinase 1 (PLK1) inhibitor. In the nine months ended September 30, 2024, the company reported total revenues of $0.5 million, an increase from $0.3 million in the same period of 2023, indicating growth in sales efforts .
Partnerships with pharmaceutical distributors
Cardiff Oncology actively engages in partnerships with pharmaceutical distributors to enhance the reach of its products. These partnerships are essential for expanding market access and improving distribution efficiency. The company has established collaborations that allow it to leverage the distribution networks of established pharmaceutical partners, facilitating broader availability of its therapies. No specific financial amounts were disclosed for these partnerships in the recent reports, but the strategic alliances are crucial for the commercialization of its therapies .
Online platforms for patient education and engagement
Cardiff Oncology utilizes online platforms to educate patients and engage them in their treatment processes. These platforms serve as resources for patients to learn about onvansertib and other treatment options. The company emphasizes the importance of patient engagement in clinical trials and treatment adherence. While financial metrics directly related to online engagement initiatives are not specified, such platforms are instrumental in driving awareness and potentially influencing sales indirectly .
| Channel Type | Description | Recent Financial Metrics |
|---|---|---|
| Direct Sales | Sales efforts targeting healthcare providers | Total revenues of $0.5 million (2024), up from $0.3 million (2023) |
| Partnerships | Collaborations with pharmaceutical distributors | No specific financial metrics disclosed |
| Online Platforms | Patient education and engagement initiatives | No specific financial metrics disclosed |
Cardiff Oncology, Inc. (CRDF) - Business Model: Customer Segments
Patients with specific cancer types, particularly those with KRAS mutations
Cardiff Oncology focuses on patients with specific cancer types, particularly those harboring KRAS mutations. KRAS mutations are prevalent in various cancers, notably in metastatic colorectal cancer (mCRC), pancreatic ductal adenocarcinoma (PDAC), and non-small cell lung cancer (NSCLC). In the United States, it is estimated that around 30,000 patients are diagnosed with mCRC annually with KRAS mutations, and over 60% of pancreatic cancer patients possess KRAS mutations, representing a significant target population for Cardiff's therapies.
Oncologists and healthcare professionals
The company also serves oncologists and healthcare professionals who treat cancer patients. These professionals are crucial in the adoption of Cardiff's therapies, particularly the lead drug candidate, onvansertib, a Polo-like Kinase 1 (PLK1) inhibitor. As of September 30, 2024, Cardiff reported that the increasing number of clinical trials and collaborations with major cancer treatment centers, such as Dana-Farber Cancer Institute, is enhancing their visibility among oncologists. The company is actively engaged in over 5 clinical trials across various cancer types, which positions it to capture the interest of oncologists looking for innovative treatment options.
Researchers and academic institutions in oncology
Cardiff Oncology also targets researchers and academic institutions involved in oncology. Collaborations with these entities are essential for advancing research and development. The company has established partnerships with several academic institutions for clinical trials and research initiatives. For instance, the ongoing trials of onvansertib involve collaboration with institutions that focus on understanding the mechanisms of cancer resistance, which is critical for developing effective treatments. In 2024, Cardiff announced collaborations with 3 prestigious research institutions to enhance the development of its drug candidates.
| Customer Segment | Key Characteristics | Market Size/Statistics |
|---|---|---|
| Patients with KRAS mutations | Focus on specific cancer types (mCRC, PDAC, NSCLC) | Estimated 30,000 new mCRC cases annually in the U.S. with KRAS mutations. |
| Oncologists and healthcare professionals | Engaged in treatment decisions and clinical trials | Over 5 active clinical trials involving onvansertib. |
| Researchers and academic institutions | Focus on oncology research and clinical trials | Collaborations with 3 major research institutions in 2024. |
Cardiff Oncology, Inc. (CRDF) - Business Model: Cost Structure
High Research and Development Costs
Cardiff Oncology, Inc. incurs significant research and development (R&D) expenses, reflecting its focus on drug development. For the nine months ended September 30, 2024, total R&D expenses amounted to $27.14 million, compared to $25.09 million for the same period in 2023, indicating an increase of $2.05 million year-over-year. The breakdown of R&D expenses is as follows:
| Expense Category | 2024 (in thousands) | 2023 (in thousands) | Increase (Decrease) (in thousands) |
|---|---|---|---|
| Salaries and Staff Costs | $5,161 | $4,475 | $686 |
| Stock-Based Compensation | $1,223 | $985 | $238 |
| Clinical Trials, Outside Services, and Lab Supplies | $19,355 | $18,118 | $1,237 |
| Facilities and Other | $1,401 | $1,516 | $(115) |
| Total R&D Expenses | $27,140 | $25,094 | $2,046 |
Operational Expenses Related to Clinical Trials
Cardiff's operational expenses are heavily influenced by ongoing clinical trials, which are essential for its lead drug candidate, onvansertib. The company has reported a significant portion of its R&D budget allocated to these trials, with clinical trials and associated outside services accounting for $19.36 million in the nine months ended September 30, 2024. This cost structure is crucial for the advancement of their clinical programs.
Administrative and Compliance Costs
Administrative and compliance costs also represent a substantial part of Cardiff's operational expenditures. For the nine months ended September 30, 2024, selling, general and administrative (SG&A) expenses totaled $9.47 million, down from $10.32 million in the previous year, reflecting a decrease of $0.85 million.
| SG&A Expense Category | 2024 (in thousands) | 2023 (in thousands) | Increase (Decrease) (in thousands) |
|---|---|---|---|
| Salaries and Staff Costs | $2,447 | $2,888 | $(441) |
| Stock-Based Compensation | $2,333 | $2,615 | $(282) |
| Outside Services and Professional Fees | $3,326 | $3,102 | $224 |
| Facilities and Other | $1,365 | $1,713 | $(348) |
| Total SG&A Expenses | $9,471 | $10,318 | $(847) |
The decrease in SG&A expenses is attributed to reduced salaries and staff costs due to an employee severance agreement, alongside lower stock-based compensation and facility costs. Overall, Cardiff Oncology’s cost structure indicates a strategic emphasis on managing operational costs while investing heavily in R&D to drive future growth.
Cardiff Oncology, Inc. (CRDF) - Business Model: Revenue Streams
Royalties from Licensed Drugs
Cardiff Oncology generates revenue through royalties from various licensed drugs. For the nine months ended September 30, 2024, the company reported total royalty revenues of $532,000, compared to $332,000 for the same period in 2023 . This revenue is primarily derived from sales-based or usage-based royalties on intellectual property licenses unrelated to their lead drug onvansertib. The revenue recognition of these royalties depends on the timing and overall sales activities of the licensees .
Potential Future Sales of Proprietary Drugs
Cardiff Oncology is in the early stages of drug development, specifically with onvansertib, which is undergoing clinical trials. The company cannot currently estimate the potential future sales from this drug due to uncertainties in development timelines, regulatory approvals, and market conditions. However, the potential for substantial revenue exists if onvansertib receives regulatory approval and achieves commercial success . The company has also indicated that significant development and commercial milestones, as well as royalties based on sales volume, will be part of their revenue structure once products are brought to market .
Grants and Funding for Clinical Research Projects
In addition to royalties and potential drug sales, Cardiff Oncology seeks grants and funding to support its clinical research projects. As of September 30, 2024, the company reported interest income of $2.5 million for the nine months ended, primarily from short-term investment portfolios . The company has been actively engaging with various funding sources to support its research and development efforts, which is crucial given their ongoing net losses and the need for additional capital .
| Revenue Source | Q3 2024 Revenue | Q3 2023 Revenue | Notes |
|---|---|---|---|
| Royalties from Licensed Drugs | $532,000 | $332,000 | Increased revenue from sales-based royalties . |
| Interest Income | $2.5 million | $3.1 million | Income from short-term investments . |
| Potential Future Sales from Onvansertib | N/A | N/A | Still in clinical trial phases; revenue not yet realized . |
Updated on 16 Nov 2024
Resources:
- Cardiff Oncology, Inc. (CRDF) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Cardiff Oncology, Inc. (CRDF)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Cardiff Oncology, Inc. (CRDF)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.